Top ▲

Allergic conjunctivitis

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:1193
Name:Allergic conjunctivitis
Associated with:0 target
8 immuno-relevant ligands
Description
Chronic inflammation of the conjunctiva involing red, itchy, and watery eyes caused by exposure to an allergen or irritant.
Database Links
Disease Ontology: DOID:11204

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols

No target related data available for Allergic conjunctivitis

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
olopatadine
Immuno Disease Comments: Approved drug for allergic conjunctivitis.
Clinical Use: Olopatadine is contained in opthalmic solutions used to treat the symptoms of seasonal allergic conjunctivitis, including itching, redness and swelling. | View clinical data
Bioactivity Comments: We have been unable to find publicly available affinity data for this drug at its proposed molecular target to substantiate its MMOA, and have therefore not tagged a primary drug target. | View biological activity
lodoxamide
Immuno Disease Comments: Approved drug for allergic (non-infectious) occular inflammation.
Clinical Use: Lodoxamide is used in opthalmic solutions to treat occular inflammation (keratitis or conjunctivitis) caused by the allergic response. | View clinical data
Bioactivity Comments: The precise mechanism of acton/primary molecular target of mast cell stabilizers is not fully resolved, so we have not associated any protein targets with this drug.
Lodoxamide inhibits the migration of THP-1 cells in vitro, in a GPR35-dependent manner [2]. | View biological activity
fluorometholone
Immuno Disease Comments: A topically applied corticosteroid used to treat inflammatory conjunctivitis.
Clinical Use: Fluorometholone is used to treat inflammatory conjunctivitis. | View clinical data
loteprednol etabonate
Immuno Disease Comments: A corticosteroid used to treat ocular inflammation.
Clinical Use: Used to treat eye swelling caused by surgery, infection, allergies, and other conditions. | View clinical data
diphenylpyraline
Immuno Disease Comments: Antihistamine approved for allergic conjunctivitis
Clinical Use: Diphenylpyraline is an antihistamine used to treat allergic rhinitis, hay fever, and allergic skin disorders. There is no information regarding approval for clinical use of this drug on the US FDA website. Other national approval agencies may have granted marketing authorisation. | View clinical data
Bioactivity Comments: We have been unable to find publicly available affinity data for this drug at its proposed molecular target to substantiate its MMOA, and have therefore not tagged a primary drug target. | View biological activity
alcaftadine
Immuno Disease Comments: Approved drug for allergic conjunctivitis.
Clinical Use: Used in an opthalmic solution to treat the symptoms of allergic conjunctivitis. | View clinical data
Bioactivity Comments: We have been unable to find publicly available affinity data for this drug at its proposed molecular target to substantiate its MMOA, and have therefore not tagged a primary drug target. | View biological activity
cromoglicic acid
Immuno Disease Comments: Mast cell stabiliser used to treat allergic conjunctivitis.
Clinical Use: Cromoglicic acid is available in different formulations; nasal spray is used to treat allergic rhinitis, nebulizer solution to treat asthma, eye drops to treat allergic conjunctivitis and an oral form to treat mastocytosis, dermatographic urticaria and ulcerative colitis. Clinical use in asthma has largely been replaced by the more convenient leukotriene receptor antagonists. | View clinical data
Bioactivity Comments: As the precise MMOA of this drug has not been fully resolved, we have not tagged a primary drug target in this case. | View biological activity
navamepent
Immuno Disease Comments: Phase 2 clinical trial NCT01639846 has been completed.
Clinical Use: Phase 2 trials in dry eye syndrome (keratoconjunctivitis sicca), allergic conjunctivitis, and inflammation and pain following cataract surgery have been completed. | View clinical data
Bioactivity Comments: Bioactivity with respect to effects on occular tissues and occular inflammation in model animals is reported in US20140275247A1, but no target interaction is specified [1]. | View biological activity

References

Show »

1. Gjorstrup P, Schwartz CE. (2016) Compositions and methods for the treatment of inflammation. Patent number: US20140275247A1. Assignee: ANIDA PHARMA Inc. Priority date: 13/04/2013. Publication date: 19/04/2016.

2. Park SJ, Lee SJ, Nam SY, Im DS. (2018) GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17?. Br J Pharmacol, 175 (1): 154-161. [PMID:29068046]